Altor BioScience Corporation
http://www.altorbioscience.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Altor BioScience Corporation
Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy
The US FDA approved Day One’s pediatric brain cancer drug Ojemda, ImmunityBio’s bladder cancer immunotherapy Anktiva, an uncomplicated UTI claim for Utility Therapeutics’ Pivya, which has a long history in Europe, and Pfizer’s hemophilia B gene therapy Beqvez.
Deal Watch: Merck KGAA Teams With AI Biotechs On Drug Discovery Efforts
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
CEPI CEO On Tackling The Next Pandemic Threat, F1 Pit Stop Operational Excellence
BioAsia 2023: CEPI's CEO, Dr Richard Hatchett, talks about viruses with pandemic potential, enhanced ‘spillover risk’ and delivering on operational excellence to get to the mission of having vaccines ready for initial authorization within 100 days of identification of a pandemic pathogen.
Tech Transfer Roundup: MD Anderson, Replay Found Allogeneic TCR-NK Cell Therapy Play Syena
Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- NantWorks, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice